Atypical vitelliform macular dystrophy misdiagnosed as chronic central serous chorioretinopathy: case reports
© Lee et al.; 2012
Received: 26 November 2011
Accepted: 6 July 2012
Published: 20 July 2012
To report two cases of atypical vitelliform macular dystrophy misdiagnosed as chronic central serous chorioretinopathy.
Two patients with incidentally discovered abnormalities of the retina without specific symptoms were referred to our hospital for consultation. Bilateral macula atrophic lesions were observed and optical coherence tomography revealed serous retinal detachment in the macula. Fluorescein angiography showed multiple leakages around the central hypofluorescent area and indocyanine green angiography showed partially dilated choroidal vessels. Fundus autofluorescence (FAF) showed a decreasing pattern of autofluorescence in the subretinal fluid area, and increasing autofluorescence at the border of the serous retinal detachment. Both patients were diagnosed with chronic central serous chorioretinopathy. Photodynamic therapy and intravitreal bevacizumab injection were administered for engorged choroidal vessels during follow-up, but neither patient showed improvement in symptoms or ophthalmologic findings. Based on re-evaluation by fundus photography, optical coherence tomography, fluorescein angiography, and comparison of the results of FAF with the first visit, vitelliform macular dystrophy was suspected and a definite diagnosis was made by electrooculography and genetic testing.
In patients with continuous serous retinal detachment without response to photodynamic therapy or intravitreal bevacizumab injection, careful fundus exam and FAF can be used to diagnose atypical vitelliform macular dystrophy.
Vitelliform macular dystrophy (VMD) is an autosomal-dominant disease that can cause a gene mutation of bestrophin-1 (Best-1). This gene codes for a Ca2+-sensitive Cl− channel protein located on the basolateral membrane of the retinal pigment epithelial cells [1–5]. There are several disease-causing mutations and the phenotypic appearance varies with the stage of the disease [6, 7]. Previously, it was believed that congenital Best disease, adult-onset VMD, and autosomal dominant vitreoretinochoroidopathy were different disease entities. The identification of mutations in the Best1 gene, however, altered this notion and revealed that most individuals with these phenotypes had mutations in the same genes [8, 9].
VMD can develop in various age groups, is usually bilateral, and induces a severe decrease of vision in the early stage, but in some cases visual acuity loss progresses insidiously. The typical fundus finings of VMD include a solitary, round or oval, slightly elevated, yellowish, subretinal lesion of the fovea [10, 11]. Optical coherence tomography (OCT) shows thick hyper-reflective structures in the retinal pigmented epithelium (RPE) layer or between the RPE layer and photoreceptor layer, and serous retinal detachment . Fluorescence angiography reveals early blockages and late intense hyperfluorescent circles with hypofluorescent central zones. Fundus autofluorescence (FAF) findings vary, but usually show hyperautofluorescence at the lesion site . A decrease in the Arden ratio in the electrooculogram (EOG) is a pathognomic characteristic .
There is no specific treatment for VMD, but regular ophthalmologic examinations annually or twice annually to determine the occurrence of complications or comorbidities are necessary. Patients diagnosed with VMD should be frequently evaluated with an Amslers grid to elucidate changes or decreases in vision. As this is a genetic disorder, family members should also be examined. Some case reports indicate that photodynamic therapy and antivascular endothelial growth factor are effective against choroidal neovascularization, but to date there are no clinically established treatments available [15, 16].
Here we report two cases of atypical VMD in patients who were misdiagnosed with chronic central serous chorioretinopathy (CSC) and did not respond to either photodynamic therapy or intravitreal bevacizumab injection.
VMD is a rare disease with autosomal dominant inheritance. It can occur in any age group, but when it is detected in younger patients between 3 and 15 years of age, it is considered to be a Best vitelliform macular dystrophy, and in patients ages between 30 and 50 years, it is considered to be adult-onset VMD with differences in the clinical appearance. It was recently discovered, however, that both are due to abnormalities of the Best1 gene with different phenotypes and its primary cause is abnormalities in bestrophin function [8, 9].
Typical fundus findings in VMD are egg yolk-like, round or oval, lesions found in the bilateral macula. The exact location of the deposits in the retina is unclear, but based on spectral domain-OCT , they are located beneath the sensory retina, causing changes in the photoreceptor inner segment/outer segments. The cause of the egg yolk-like yellowish deposits is unknown, but may be due to unphagocytosed outer segments that accumulate because of the lack of apposition of the outer membrane segments to the RPE. The persistence of the material in the subretinal space increases the likelihood of the formation of lipofuscin precursors, which are autofluorescent and susceptible to oxidative damage . In histologic examination, these lipofuscins appear as egg yolk-like lesions . In the advanced disease state, lipofuscins normally get reabsorbed or disappear, and cause atrophy in the RPE. The findings of fluorescein angiography vary based on the yellowish lesions, usually hypofluorescence in the central lesions and a window defect can be seen, and in FAF, the fluorescence of the lesions is irregularly increased or decreased .
In EOG, a decrease in the Arden ratio is a distinctive feature of VMD , due to a defect in Ca2+ activated Cl- channels of the RPE basolateral membrane that expresses bestrophin. Until recently, EOG has been the most accurate test for determining the cause of the disease as well as genetic examination.
At a young age, bilateral neurosensory retinal detachment can be caused by infections, inflammation, collagen-vascular disease, tumor, age-related macular degeneration, polypoidal choroidal vasculopathy, and CSC. In the presented cases, there were no symptoms of infection or inflammation, and both systemic disease and tumor were also excluded. Age-related macular degeneration usually occurs at an advanced age, and polypoidal choroidal vasculopathy can occur at a young age, but polypoidal dilation was not observed on indocyanine green angiography so it was excluded. Therefore, chronic CSC was suspected based on the examinations and clinical features in these cases.
Based on the clinical features, the patients were diagnosed with chronic CSC and received photodynamic treatment for months. Case 1 received intravitreal bevacizumab injection and laser photocoagulation therapy to coagulate the leaking points but serous retinal detachment persisted for 2 years. Also, there was no change in the autofluorescence for several years compared to the baseline.
In the case of CSC, as the disease state progresses hyperautofluorescence or hypoautofluorescence can be seen in FAF, but it is uncommon to find an overall decrease in autofluorescence in the center and an increase in autofluorescence at the border of the serous retinal detachment in CSC. Normally, egg yolk-like lesions in VMD are lipofuscins, which can lead to an increase in autofluorescence in the lesion areas. In these cases, the autofluorescence decreased due to the absorption of lesions in the central area and continuous serous retinal detachment, and autofluorescence increased due to the existence of deposits at the bottom border of the serous retinal detachment and around the area of the serous detachment. Especially in the second case, fundus photography and slit lamp examination revealed no yellowish deposits, but FAF showed hyperautofluorescence in the border of serous retinal detachment, so it was very helpful for making a diagnosis.
In patients who do not respond to treatment for continuous bilateral serous retinal detachment, it is necessary to differentiate atypical cases of VMD with careful ophthalmologic examination. FAF may be helpful for diagnosis.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor in-Chief of this journal.
- Forsman K, Graff C, Nordström S, Johansson K, Westermark E, Lundgren E, et al: The gene for Best’s macular dystrophy is located at 11q13 in a Swedish family. Clin Genet. 1992, 42: 156-159.View ArticlePubMedGoogle Scholar
- Stone EM, Nichols BE, Streb LM, Kimura AE, Sheffield VC: Genetic linkage of vitelliform macular degeneration (Best’s disease) to chromosome 11q13. Nat Genet. 1992, 1: 246-250. 10.1038/ng0792-246.View ArticlePubMedGoogle Scholar
- Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, et al: Identification of the gene responsible for Best dystrophy. Nat Genet. 1998, 19: 241-247. 10.1038/915.View ArticlePubMedGoogle Scholar
- Marmorstein AD, Marmorstein LY, Rayborn M, Wang X, Hollyfield JG, Petrukhin K: Bestrophin, the product of the Best vitelliform macular dystrophy gene (VMD2), localizes to the basolateral plasma membrane of the retinal pigment epithelium. Proc Natl Acad Sci U S A. 2000, 97: 12758-12763. 10.1073/pnas.220402097.View ArticlePubMedPubMed CentralGoogle Scholar
- Sun H, Tsunenari T, Yau KW, Nathans J: The vitelliform macular dystrophy protein defines a new family of chloride channels. Proc Natl Acad Sci U S A. 2002, 99: 4008-4013. 10.1073/pnas.052692999.View ArticlePubMedPubMed CentralGoogle Scholar
- Gass JDM: Stereoscopic Atlas of Macular Disease: Diagnosis and Treatment. 1997, St. Louis: Mosby, 304-311. 4Google Scholar
- Deutman AF, Hoyng CB: Macular dystrophies. Edited by: Ryan SJ, Ogden TE, Hinton DR, Schachat AP. 2001, St. Louis: Mosby, 1210-1257. 3Google Scholar
- Boon CJ, Klevering BJ, Leroy BP, Hoyng CB, Keunen JE, den Hollander AI: The spectrum of ocular phenotypes caused by mutations in the BEST1 gene. Prog Retin Eye Res. 2009, 28: 187-205. 10.1016/j.preteyeres.2009.04.002.View ArticlePubMedGoogle Scholar
- Booij JC, Boon CJ, van Schooneveld MJ, ten Brink JB, Bakker A, de Jong PT, et al: Course of visual decline in relation to the Best1 genotype in vitelliform macular dystrophy. Ophthalmology. 2010, 117: 1415-1422. 10.1016/j.ophtha.2009.11.044.View ArticlePubMedGoogle Scholar
- Gass JDM: A clicopathologic study of a peculiar foveomacular dystrophy. Trans Am Ophthalmol Soc. 1974, 72: 139-156.PubMedPubMed CentralGoogle Scholar
- Lim JI, Enger C, Fine SL: Foveomacular dystrophy. Am J Ophthalmol. 1994, 117: 1-6.View ArticlePubMedGoogle Scholar
- Spaide RF, Noble K, Morgan A, Freund KB: Vitelliform macular dystrophy. Ophthalmology. 2006, 113: 1392-1400. 10.1016/j.ophtha.2006.03.023.View ArticlePubMedGoogle Scholar
- Chung JE, Spaide RF: Fundus autofluorescence and vitelliform macular dystrophy. Arch Ophthalmol. 2004, 122: 1078-1079. 10.1001/archopht.122.7.1078.View ArticlePubMedGoogle Scholar
- Deutman AF: Electro-oculography in families with vitelliform dystrophy of the fovea. Detection of the carrier state. Arch Ophthalmol. 1969, 81: 305-316. 10.1001/archopht.1969.00990010307001.View ArticlePubMedGoogle Scholar
- Andrade RF, Farah ME, Costa RA: Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization in best disease. Am J Ophthalmol. 2003, 136: 1179-1181. 10.1016/S0002-9394(03)00711-6.View ArticlePubMedGoogle Scholar
- Leu J, Schrage NF, Degenring RF: Choroidal neovascularization secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2007, 245: 1723-1725. 10.1007/s00417-007-0604-7.View ArticlePubMedGoogle Scholar
- Puche N, Querques G, Benhamou N, Tick S, Mimoun G, Martinelli D, et al: High-resolution spectral domain optical coherence tomography features in adult onset foveomacular vitelliform dystrophy. Br J Ophthalmol. 2010, 94: 1190-1196. 10.1136/bjo.2009.175075.View ArticlePubMedGoogle Scholar
- O’Gorman S, Flaherty WA, Fishman GA, Berson EL: Histopathologic findings in Best’s vitelliform macular dystrophy. Arch Ophthalmol. 1988, 106: 1261-1268. 10.1001/archopht.1988.01060140421045.View ArticlePubMedGoogle Scholar
- Renner AB, Tillack H, Kraus H, Kohl S, Wissinger B, Mohr N, et al: Morphologic and functional charateristics in adult vitelliform macular dystrophy. Retina. 2004, 24: 929-939. 10.1097/00006982-200412000-00014.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2415/12/25/prepub
This article is published under license to BioMed Central Ltd. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.